Neogen (NEOG) has just posted Q3 2026 results with revenue of US$211.2 million and a basic EPS loss of US$0.08, alongside trailing twelve month revenue of US$870.6 million and a basic EPS loss of US$2.80. This keeps the focus firmly on how efficiently the business is converting sales into earnings. Over recent quarters the company has seen revenue move from US$231.3 million in Q2 2025 to US$225.5 million in Q4 2025, then to US$209.2 million in Q1 2026 and US$224.7 million in Q2 2026 before landing at US$211.2 million in Q3 2026, while EPS has swung between a Q1 2026 profit of US$0.17 and losses in the surrounding periods. That mix of steady sales and persistent losses puts margins, not just top line size, at the center of how investors are likely to read this update.
See our full analysis for Neogen.With the numbers on the table, the next step is to set them against the most widely held stories about Neogen to see which narratives hold up and which start to look out of sync with the margin picture.
See what the community is saying about Neogen
TTM losses of US$608.8 million on flat revenue
- Over the last twelve months, Neogen booked US$870.6 million in revenue and a net loss of US$608.8 million, with trailing revenue growth of about 0.3% per year and losses having grown at an annualized rate of 80.6% over five years.
- Bears argue the combination of modest top line movement and deep losses supports a cautious stance, and the recent quarterly pattern lines up with that concern:
- Net income moved from a US$612.2 million loss in Q4 2025 to a US$17.0 million loss in Q3 2026, while revenue stayed in a tight band between US$209.2 million and US$231.3 million across the last six quarters, so profitability has not tracked with sales stability.
- On a trailing basis, the company remains unprofitable and is not forecast in the provided data to reach profitability over the next three years, which fits the bearish view that current operations are not yet set up to convert this revenue base into positive earnings.
P/S of 2.5x and DCF fair value of US$26.11
- The stock trades on a P/S of 2.5x compared with 2.6x for the broader US Medical Equipment industry and 3.2x for peers, while a DCF fair value of US$26.11 sits well above the current share price of US$9.42.
- Bullish investors point to this gap as a potential opportunity, but the reported figures make the valuation debate very specific:
- The DCF fair value in the data implies the shares trade at a large discount to that estimate, yet the trailing twelve month loss of US$608.8 million means the thesis leans heavily on future margin repair rather than current profitability.
- With revenue growth essentially flat at 0.3% per year on the trailing view and forecasts in the dataset still showing losses over the next three years, the favorable P/S and DCF fair value only strongly support the bullish case if an investor is comfortable underwriting a long runway for earnings improvement that is not yet visible in the reported income statement.
Q3 loss of US$17 million versus Q1 profit of US$36.3 million
- Within the 2026 financial year, Neogen moved from a net profit of US$36.3 million in Q1 2026 to losses of US$15.9 million in Q2 and US$17.0 million in Q3, even as revenue hovered between US$209.2 million and US$224.7 million across those three quarters.
- Analysts looking for a balanced middle ground between bulls and bears tend to focus on how this choppy pattern affects confidence in any turnaround story:
- On one hand, the Q1 2026 profit shows the business can print a positive quarter, which lines up with the consensus idea that operational fixes and portfolio focus might eventually support higher quality earnings.
- On the other hand, the quick move back to losses in Q2 and Q3 2026, together with trailing twelve month losses of more than US$600 million, backs the view that integration and margin issues are still very much present and that any improvement case rests on several years of consistent execution rather than a single strong period.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Neogen on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Want to see whether this cautious but open minded tone matches your own take on Neogen's story? Check the data for yourself, weigh both sides of the argument, and pay close attention to the 1 key reward and 1 important warning sign.
See What Else Is Out There
Neogen's flat trailing revenue, sizeable twelve month loss of US$608.8 million, and swings between profit and loss highlight meaningful earnings and consistency risks for shareholders.
If that level of uncertainty feels uncomfortable, you can shift your attention toward companies that score better on stability and risk using the 72 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com